



Chronic Kidney and Liver Disease: From Pathophysiology to Novel Therapeutic Approaches

Guest Editor:

Dr. Henricus A.M. Mutsaers

Department of Clinical Medicine,
Aarhus University, Aarhus,
Denmark

Deadline for manuscript
submissions:

closed (15 December 2021)

Message from the Guest Editor

Dear Colleagues,

The prevalence of chronic kidney disease (CKD) and non-alcoholic fatty liver disease (NAFLD) is on the rise, and it is expected that both diseases will become leading causes of death globally. CKD is defined by a long-standing loss of renal function and is associated with an increased risk of end-stage renal disease, cardiovascular disease, and premature death. NAFLD is characterized by excessive fat accumulation in the liver, and it covers a spectrum of disease from simple steatosis to the more aggressive form of non-alcoholic steatohepatitis (NASH). Both diseases frequently exist together. Nonetheless, studies on the mechanistic link between CKD and NAFLD are sparse. A better understanding of the pathophysiological mechanisms that underlie the development and progression of both CKD and NAFLD is essential. For this Special Issue, we welcome papers that focus on the pathogenesis of CKD, NAFLD, and associated pathologies, as well as papers detailing novel therapeutic targets and therapies. Papers that investigate the link between both diseases are especially welcomed.

Dr. Henricus A.M. Mutsaers

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI